SPIGEN KOREA CO.LTD.

As of June 30, 2026, SPIGEN KOREA CO.LTD. carries a market capitalization of 169.09B, placing it among publicly traded companies globally. Its enterprise value stands at -47.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SPIGEN KOREA CO.LTD. has 5.78M shares outstanding.

As of June 30, 2026, SPIGEN KOREA CO.LTD. trades at a trailing price-to-earnings ratio of 3.24. The price-to-sales ratio is 0.35, and the price-to-book ratio stands at 0.29.

As of June 30, 2026, SPIGEN KOREA CO.LTD. maintains a current ratio of 10.00, meaning it holds 10.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.13, indicating moderate leverage, while an interest coverage ratio of 574.31 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SPIGEN KOREA CO.LTD. posted a return on equity (ROE) of 9.73, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.51 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.01, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.60, useful for judging operating efficiency across full business cycles. The company generates approximately 1.17B in revenue per employee across its workforce of 411.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.11 indicates how many times SPIGEN KOREA CO.LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, SPIGEN KOREA CO.LTD. recorded 7.53B in income tax expense. That works out to an effective tax rate of 12.55, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 60.01B, leaving 52.21B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, SPIGEN KOREA CO.LTD.'s stock has gained approximately 23.66% over the past 52 weeks. The 50-day moving average sits at 29,188.00, while the 200-day moving average is 27,168.00.

Over the twelve months ended June 30, 2026, SPIGEN KOREA CO.LTD. generated 482.37B in revenue and converted that into 52.21B in net income, yielding earnings per share of 9,086.49. EBITDA reached 54.62B, while operating income came in at 46.72B.

As of June 30, 2026, SPIGEN KOREA CO.LTD. holds 224.55B in cash and equivalents against 6.51B in total debt, resulting in a net debt position of -90.05B. Total book value stands at 573.49B, with working capital of 306.00B providing operational flexibility.

SPIGEN KOREA CO.LTD. produced 63.42B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.01B in capital expenditures, free cash flow totaled 62.41B - equivalent to 10,805.55 per share.

Over the twelve months ended June 30, 2026, SPIGEN KOREA CO.LTD. posted a gross margin of 65.49, reflecting its pricing power and cost economics. The operating margin of 9.69 and net profit margin of 10.82 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, SPIGEN KOREA CO.LTD. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 36.94, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.47, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SPIGEN KOREA CO.LTD. shareholders.

As of June 30, 2026, SPIGEN KOREA CO.LTD. has an Altman Z-Score of 5.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.